Two researchers in a cancer research laboratory
Two researchers in a cancer research laboratory - Quell Therapeutics (Quell), a biopharmaceutical UCL spinout, has raised £117 million ($156m) to trial its pioneering T Regulatory (Treg) cell therapy, designed to prevent organ rejection in liver transplant patients. The oversubscribed Series B financing round was co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company LLC. Founding investor Syncona also participated in the financing round. Quell was formed in 2019 by leading academics from UCL, King's College London and Hannover Medical School, including UCL Professors Hans Stauss and Emma Morris (both UCL Division of Infection & Immunity) - who have over fifteen years of experience in T cell engineering and gene therapy clinical trials. The company was spun-out with support from UCL Business (UCLB), UCL's commercialisation company. Quell is developing a Multi-Modular Engineered T Regulatory (Treg) Cell Therapy platform for transplantation, neuroinflammatory and autoimmune diseases, with the goal of enabling transplant patients and patients with autoimmune conditions to live without taking conventional immunosuppressive medication.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
